The US Food and Drug Administration on Wednesday authorised Pfizer's Paxlovid pill, the first anti-Covid-19 treatment pill to be authorised in the country. It will be used to treat high-risk patients with moderate to severe disease within five days of symptom onset. Pfizer said it was ready to commence delivery of the pill immediately.
The latest news comes on the back of seperate positive pandemic developments. Namely, a recent study released by Scottish scientists showed Omicron infection to be associated with about a two-thirds reduced risk of hospitalisation, a conclusion in fitting with similar studies conducted in South Africa.
Market Reaction
Markets have switched from trading in a quite a subdued fashion earlier in the session to more of a risk on mode in recent trade, with stocks, crude oil and risk sensitive currencies all gaining in recent trade. The aforementioned positive pandemic newsflow is likely contributing to a sense of optimism that while Omicron is a threat to the global economy, it does not look set to deliver a lasting blow to growth, given its lesser severity, high vaccination rates in developed countries and the upcoming rollout of effective treatments.
Note: All information on this page is subject to change. The use of this website constitutes acceptance of our user agreement. Please read our privacy policy and legal disclaimer. Opinions expressed at FXstreet.com are those of the individual authors and do not necessarily represent the opinion of FXstreet.com or its management. Risk Disclosure: Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any doubts.
Recommended content
Editors’ Picks

EUR/USD advances toward 1.1300 on broad USD weakness
EUR/USD gathers bullish momentum and rises toward 1.1300 on Monday. The US Dollar (USD) stays under strong selling pressure following Moody's downgrade of the US sovereign credit rating, fuelling the pair's upside. Investors keep a close eye on comments from Fed officials.

GBP/USD extends gains toward 1.3400 as US Dollar selloff continues
GBP/USD extends its rally and approaches 1.3400 in the second half of the day on Monday. The upsurge is largely driven by renewed pressure on the US Dollar after Moody’s Investors Service downgraded the US credit rating by one notch, from Aaa to Aa1.

Gold rebounds toward $3,250 as markets turn risk-averse
Gold gains traction and rises toward $3,250 after ending the previous week in negative territory. Markets adopt a cautious stance on Monday and XAU/USD benefits from safe-haven flows as investors assess Moody's decision to downgrade the US government's credit rating.

Stock futures contract after Moody's US debt downgrade Premium
US stocks opened on a sour note on Monday following the fallout late Friday when the Moody's credit rating agency lowered its outlook on US debt from Aaa to Aa1. Moody's had already had the US government on watch for a year and half, so the actual downgrade shouldn't have surprised investors too much.

China April slowdown shows the impact of economic uncertainty
Trade war uncertainty is denting Chinese confidence, resulting in slower economic activity in April. Retail sales and fixed-asset investment both underperformed forecasts amid heightened caution. Yet the impact on manufacturing was less than feared.